^
    8ms
    Gene expression analysis in circulating tumour cells to determine resistance to CDK4/6 inhibitors plus endocrine therapy in HR + /HER2- metastatic breast cancer patients. (PubMed, J Transl Med)
    CTC gene expression provides information about treatment outcomes in HR + /HER2- metastatic BC patients receiving CDK4/6i plus ET and could guide personalized strategies and improve prognosis.
    Journal • Circulating tumor cells
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • CCND1 (Cyclin D1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CDK6 (Cyclin-dependent kinase 6) • PRKCB (Protein Kinase C Beta) • CDC7 (Cell Division Cycle 7) • MAPK3 (Mitogen-Activated Protein Kinase 3)
    |
    HER-2 negative • ROS1 positive
    |
    nCounter® PanCancer Pathways Panel
    10ms
    A Novel Molecular Profile of Hormone-Sensitive Prostate Cancer Defines High Risk Patients. (PubMed, Cancer Med)
    The differential genetic signature identified between the two study groups revealed novel biomarkers in mHSPC, additionally suggesting new therapeutic targets within the hormone sensitive phase, such as AKT2. Further prospective larger cohort studies are needed to assess the prognostic value of our findings and their exact role in prostate cancer progression.
    Retrospective data • Journal
    |
    AKT2 (V-akt murine thymoma viral oncogene homolog 2) • NR4A1 (Nuclear Receptor Subfamily 4 Group A Member 1)
    |
    nCounter® PanCancer Pathways Panel
    1year
    Potential predictive biomarkers for a fibroblast growth factor receptor (FGFR) inhibitor: Phase 1b trial of tasurgratinib (E7090) with endocrine therapies (ET) for ER+, HER2+ recurrent/metastatic breast cancer (BC) resistant to CDK4/6 inhibitors (SABCS 2024)
    Part 1 included treatment with fulvestrant (FUL) 500 mg + E7090 (105 or 140 mg) or exemestane (EXE) 25 mg + E7090 (105 or 140 mg). These results emphasize that FGFR pathway activation evaluated with mRNA expression of selected genes at BL—rather than FGFR gene abnormalities—is a key molecular determinant for sensitivity to E7090, an FGFR inhibitor. Future validation of these biomarkers is necessary in a larger population of people with ER+/HER2− BC.
    P1 data • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • FGF3 (Fibroblast growth factor 3) • FGF4 (Fibroblast growth factor 4)
    |
    ER mutation • FGFR1 expression
    |
    FoundationOne® CDx • nCounter® PanCancer Pathways Panel
    |
    fulvestrant • exemestane • Tasfygo (tasurgratinib)
    1year
    Assessing chordoma heterogeneity: insights from primary and recurrent expression patterns (EORTC-NCI-AACR 2024)
    Our initial findings distinguish recurrent chordomas from their primary counterparts based on cancer gene expression changes that encourage growth and proliferation, remodel the bone matrix environment, and evade the immune system. Continued investigation is needed to assemble a broader patient sample. Examining the pathways and genetic mutations across the chordoma disease progression may reveal novel therapeutic avenues for recurrent chordomas.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CHI3L1 (Chitinase 3-like 1) • TGFB1 (Transforming Growth Factor Beta 1) • CDH2 (Cadherin 2) • ITGA3 (Integrin Subunit Alpha 3)
    |
    nCounter® PanCancer Pathways Panel
    over1year
    "Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+. (clinicaltrials.gov)
    P=N/A; Trial completion date: Jan 2024 --> Jan 2025
    Trial completion date
    |
    EPCAM (Epithelial cell adhesion molecule) • VIM (Vimentin)
    |
    nCounter® PanCancer Pathways Panel
    over1year
    Genomic landscape of metaplastic breast cancer from the AACR GENIE database (ESMO-BC 2024)
    PIK3CA is also prevalent in MpBC and potentially targetable. Our findings may inform the development of novel targeted therapeutic regimens and improve outcomes for this rare but aggressive breast cancer subtype.
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • KMT2C (Lysine Methyltransferase 2C) • FAT1 (FAT atypical cadherin 1) • RAD21 (RAD21 Cohesin Complex Component) • TGFB1 (Transforming Growth Factor Beta 1) • RECQL4( RecQ Like Helicase 4)
    |
    TP53 mutation • PIK3CA mutation • PIK3CA amplification
    |
    nCounter® PanCancer Pathways Panel
    almost2years
    Subtyping of Small Cell Carcinoma Remains Unchanged After Recurrence, Supported by RNA Expression and Highly Concordant IHC Approaches (USCAP 2024)
    The majority of recurrent SCLC retained their pre-treatment subtype, by both RNA expression and IHC evaluation. It suggests subtype is an intrinsic characteristic of SCLC regardless of treatment. IHC subtyping demonstrated high concordance with RNA expression thus can be utilized effectively in pathology practice.
    Discordant
    |
    YAP1 (Yes associated protein 1) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)
    |
    nCounter® PanCancer Pathways Panel
    almost2years
    Targeting hepatocellular carcinoma: evaluation of vicinal diaryl isoxazole and pyrazole derivatives with implications for oxidative stress and senescence-mediated anti-tumor mechanisms (LCS 2024)
    In summary, the study demonstrated the anti-tumor effects of compounds c1 and c2 associated with the induction of oxidative stress and senescence-dependent mechanisms. These compounds can be further evaluated as potential anti-cancer agents for HCC.
    Oxidative stress
    |
    CDK1 (Cyclin-dependent kinase 1)
    |
    nCounter® PanCancer Pathways Panel
    2years
    Enhanced Genomic Stability in Monomorphic Post-Transplant Lymphoproliferative Disorders Is Driven By Distinct Mechanisms Stratified By EBV Status (ASH 2023)
    Like HIV associated DLBCL, these results show that PTLD is more genomically stable than IC-DLBCL, and that genomic stability is further enhanced in EBV(+)PTLD which have increased expression of UPS related genes. In contrast, EBV(-)PTLD have increased expression of DNA damage repair genes, including RAD51. In summary, monomorphic DLBCL PTLD tumors have enhanced genomic stability that appears to be mediated by two distinct mechanisms stratified by EBV status.
    Post-transplantation
    |
    MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • EP300 (E1A binding protein p300) • CHEK1 (Checkpoint kinase 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • CCNA2 (Cyclin A2) • PCNA (Proliferating cell nuclear antigen) • DDB2 (Damage Specific DNA Binding Protein 2) • ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit) • FANCE (FA Complementation Group E) • POLG2 (DNA Polymerase Gamma 2, Accessory Subunit) • FANCB (FA Complementation Group B)
    |
    RAD51 overexpression • ATM expression
    |
    nCounter® PanCancer Pathways Panel
    2years
    "Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+. (clinicaltrials.gov)
    P=N/A; Trial completion date: Jun 2023 --> Jan 2024
    Trial completion date
    |
    EPCAM (Epithelial cell adhesion molecule) • VIM (Vimentin)
    |
    CA9 expression
    |
    nCounter® PanCancer Pathways Panel
    over2years
    Fibroblast Growth Factor 11 (FGF11) Promotes Progression and Cisplatin Resistance Through the HIF-1α/FGF11 Signaling Axis in Ovarian Clear Cell Carcinoma. (PubMed, Cancer Manag Res)
    Mechanically, FGF11 was regulated by hypoxia-inducible factor-1α (HIF-1α) to modulate the DDP sensitivity. FGF11 was highly expressed in platinum-resistant OCCC tissues, promoting progression and resistance to DDP through the HIF-1α/FGF11 signaling axis.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    HIF1A expression
    |
    nCounter® PanCancer Pathways Panel
    |
    cisplatin
    over2years
    Identification of potential biomarkers for diagnosis of lung adenocarcinoma (ERS 2023)
    We identified a 78-gene signature that might help define a more accurate diagnosis for lung adenocarcinoma.; Cell and molecular biology; Endoscopy and interventional pulmonology; Pulmonary function testing; Epidemiology; Surgery; Public health; General respiratory patient care; Imaging
    TLR4 (Toll Like Receptor 4)
    |
    nCounter® PanCancer Pathways Panel